Skip to main content

Loading market data...

JAZZ

Jazz Pharmaceuticals plc

NASDAQ • United states

$211.81

-$1.95

(-0.91%)

Source: Yahoo Finance · Quote time Oct 21, 2026 15:49 GMT+0000

Management
Credibility
Score

Jazz Pharmaceuticals plc (JAZZ)

Unavailable

Quotes may be delayed

$13.75B

Market Cap

161,186

Volume

14.6

P/E Ratio

Unavailable

Div Yield

Jazz Pharmaceuticals plc Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

9 Oct 2026

Jazz Pharmaceuticals plc reported A director or senior management change or compensation event

Jazz Pharmaceuticals plc filed an 8-K covering a director or senior management change or compensation event.

24 Sep 2026

Jazz Pharmaceuticals plc reported A material agreement

Jazz Pharmaceuticals plc filed an 8-K covering a material agreement, a material financing obligation, supporting financial statements or exhibits.

15 Sep 2026

Jazz Pharmaceuticals plc reported Regulation FD disclosure

Jazz Pharmaceuticals plc filed an 8-K covering Regulation FD disclosure.

1 Sep 2026

Jazz Pharmaceuticals plc reported A material agreement

Jazz Pharmaceuticals plc filed an 8-K covering a material agreement, a material financing obligation, an unregistered sale of shares, another company event, supporting financial statements or exhibits.

26 Aug 2026

Jazz Pharmaceuticals plc reported Another company event

Jazz Pharmaceuticals plc filed an 8-K covering another company event.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$1.62B

Total assets (USD)$11.08B

Shareholders' equity (USD)$4.80B

Long-term debt (USD)$3.34B

Debt due within a year (USD)$1.02B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$1.21B	$248.20M	$192.80M	$2.78	10-Q · 3 Aug 2026
Q1 2026	$1.07B	$336.60M	$293.10M	$4.43	10-Q · 5 May 2026
Q4 2025	$1.20B	$254.54M	$203.45M	Unavailable	10-K · 24 Feb 2026
Q3 2025	$1.13B	$57.51M	$251.41M	$4.08	10-Q · 5 Nov 2025
Q2 2025	$1.05B	−$686.39M	−$718.47M	−$11.74	10-Q · 6 Aug 2025
Q1 2025	$897.84M	−$55.89M	−$92.54M	−$1.52	10-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $297.72

40.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

17

⏸️

Hold

1

📉

Sell

0

18 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 15:49 UTC Targets range 229.00–337.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

6

Oct 2026

GALA RENEE D

Director, President & CEO

Open-market sale

$236.40 per share

2,000 shares

1

Oct 2026

COZADD BRUCE C

Director

Open-market sale

$230.33 per share

6,000 shares

10

Sep 2026

Patil Neena M

EVP & Chief Legal Officer

Open-market sale

$240.94 per share

1,200 shares

8

Sep 2026

GALA RENEE D

President & CEO

Tax withholding

$246.81 per share

1,967 shares

8

Sep 2026

GALA RENEE D

President & CEO

Open-market sale

$243.03 per share

2,000 shares

8

Sep 2026

Henderson Mary Elizabeth

SVP, Technical Operations

Tax withholding

$243.01 per share

1,427 shares

31

Aug 2026

Henderson Mary Elizabeth

SVP, Technical Operations

Tax withholding

$241.41 per share

2,092 shares

31

Aug 2026

Smith Mark Douglas

Director

Tax withholding

$241.42 per share

1,706 shares

31

Aug 2026

RIEDEL NORBERT G

Director

Tax withholding

$241.42 per share

1,706 shares

Top Shareholders

Blackrock, Inc.

5,968,603 shares

6.74% change

6/30/2026

Vanguard Group Inc

5,917,142 shares

0.173% change

12/31/2025

Fmr Llc

4,609,326 shares

102.54% change

6/30/2026

Vanguard Portfolio Management Llc

3,036,213 shares

1.776% change

6/30/2026

Vanguard Capital Management Llc

2,729,650 shares

3.07% change

6/30/2026

Capital World Investors

2,697,610 shares

0.906% change

6/30/2026

Lsv Asset Management

2,275,145 shares

-4.68% change

6/30/2026

Franklin Templeton Inc

2,040,250 shares

4.151% change

6/30/2026

State Street Corp

1,999,816 shares

5.718% change

6/30/2026

Dimensional Fund Advisors Lp

1,713,592 shares

-9.583% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 15:50 UTC· 18 hours ago

Research coverage and investment tools

Jazz Pharmaceuticals plc (JAZZ) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$211.81 on 21 Oct 2026. That is 60% of the way from its 52-week low of US$128.80 to its 52-week high of US$266.38. Its market capitalisation was US$13.75 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$1.21B	$248.20M	$192.80M	$2.78	—	20.5%	$397.60M	10-Q · 3 Aug 2026 (opens in a new tab)
Q1 2026	$1.07B	$336.60M	$293.10M	$4.43	—	31.5%	$388.50M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$1.20B	$254.54M	$203.45M	Unavailable	—	21.2%	$345.79M	10-K · 24 Feb 2026 (opens in a new tab)
Q3 2025	$1.13B	$57.51M	$251.41M	$4.08	—	5.1%	$459.43M	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$1.05B	−$686.39M	−$718.47M	−$11.74	—	-65.6%	$75.90M	10-Q · 6 Aug 2025 (opens in a new tab)
Q1 2025	$897.84M	−$55.89M	−$92.54M	−$1.52	—	-6.2%	$415.88M	10-Q · 7 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/3/2026	$4.89	$5.06	-3.4%
Mar 2026	5/5/2026	$5.46	$3.82	+42.9%
Dec 2025	2/24/2026	$5.76	$5.65	+2.0%
Sep 2025	11/5/2025	$6.99	$4.80	+45.6%

Cash and equivalents: $1.62B
Total assets: $11.08B
Shareholders' equity: $4.80B
Long-term debt: $3.34B
Debt due within a year: $1.02B

8-K · 9 Oct 2026 · Management change

Jazz Pharmaceuticals plc reported A director or senior management change or compensation event (opens in a new tab)

Jazz Pharmaceuticals plc filed an 8-K covering a director or senior management change or compensation event.
8-K · 24 Sep 2026 · Material agreement Signed

Jazz Pharmaceuticals plc reported A material agreement (opens in a new tab)

Jazz Pharmaceuticals plc filed an 8-K covering a material agreement, a material financing obligation, supporting financial statements or exhibits.
8-K · 15 Sep 2026

Jazz Pharmaceuticals plc reported Regulation FD disclosure (opens in a new tab)

Jazz Pharmaceuticals plc filed an 8-K covering Regulation FD disclosure.
8-K · 1 Sep 2026 · Material agreement Signed

Jazz Pharmaceuticals plc reported A material agreement (opens in a new tab)

Jazz Pharmaceuticals plc filed an 8-K covering a material agreement, a material financing obligation, an unregistered sale of shares, another company event, supporting financial statements or exhibits.
8-K · 26 Aug 2026

Jazz Pharmaceuticals plc reported Another company event (opens in a new tab)

Jazz Pharmaceuticals plc filed an 8-K covering another company event.

Insider	Date	Transaction	Shares	Average price	Filing
GALA RENEE D Director, President & CEO	6 Oct 2026	Open-market sale (S)	−2,000	$236.40	Form 4 (opens in a new tab)
COZADD BRUCE C Director	1 Oct 2026	Open-market sale (S)	−6,000	$230.33	Form 4 (opens in a new tab)
Patil Neena M EVP & Chief Legal Officer	10 Sep 2026	Open-market sale (S)	−1,200	$240.94	Form 4 (opens in a new tab)
GALA RENEE D President & CEO	8 Sep 2026	Tax withholding (F)	−1,967	$246.81	Form 4 (opens in a new tab)
GALA RENEE D President & CEO	8 Sep 2026	Open-market sale (S)	−2,000	$243.03	Form 4 (opens in a new tab)
Henderson Mary Elizabeth SVP, Technical Operations	8 Sep 2026	Tax withholding (F)	−1,427	$243.01	Form 4 (opens in a new tab)
Henderson Mary Elizabeth SVP, Technical Operations	31 Aug 2026	Tax withholding (F)	−2,092	$241.41	Form 4 (opens in a new tab)
Smith Mark Douglas Director	31 Aug 2026	Tax withholding (F)	−1,706	$241.42	Form 4 (opens in a new tab)
RIEDEL NORBERT G Director	31 Aug 2026	Tax withholding (F)	−1,706	$241.42	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	5,968,603	6.74%
Vanguard Group Inc	12/31/2025	5,917,142	0.173%
Fmr Llc	6/30/2026	4,609,326	102.54%
Vanguard Portfolio Management Llc	6/30/2026	3,036,213	1.776%
Vanguard Capital Management Llc	6/30/2026	2,729,650	3.07%
Capital World Investors	6/30/2026	2,697,610	0.906%
Lsv Asset Management	6/30/2026	2,275,145	-4.68%
Franklin Templeton Inc	6/30/2026	2,040,250	4.151%
State Street Corp	6/30/2026	1,999,816	5.718%
Dimensional Fund Advisors Lp	6/30/2026	1,713,592	-9.583%

Previous close: 213.76 USD
Day range: 211.78 – 215.13 USD
52-week range: 128.80 – 266.38 USD
Volume: 161,186
Market cap: $13.75B
Average volume: 876,697
P/E ratio: 14.6
EPS (FY 2025, diluted): −5.84 USD
Shares outstanding: 64.91M
Beta (5Y monthly): 0.36

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 15:49 UTC· 18 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:07 UTC· 2 hours ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for JAZZ yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.